

## HR 1405

Enhancing Domestic Drug Manufacturing Competitiveness Act

**Congress:** 119 (2025–2027, Current)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 18, 2025

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Feb 18, 2025)

**Official Text:** <https://www.congress.gov/bill/119th-congress/house-bill/1405>

### Sponsor

**Name:** Rep. Buchanan, Vern [R-FL-16]

**Party:** Republican • **State:** FL • **Chamber:** House

### Cosponsors (1 total)

| Cosponsor                     | Party / State | Role | Date Joined  |
|-------------------------------|---------------|------|--------------|
| Rep. Donalds, Byron [R-FL-19] | R · FL        |      | Feb 18, 2025 |

### Committee Activity

| Committee                     | Chamber | Activity    | Date         |
|-------------------------------|---------|-------------|--------------|
| Energy and Commerce Committee | House   | Referred To | Feb 18, 2025 |

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

*No related bills are listed.*

## **Enhancing Domestic Drug Manufacturing Competitiveness Act**

This bill requires the Government Accountability Office (GAO) to study and report to Congress on key regulatory barriers to pharmaceutical manufacturing in the United States.

Specifically, GAO must identify and assess, including by engaging stakeholders, barriers that impede expansion or siting of pharmaceutical manufacturing facilities in the United States or make the United States less competitive than other countries as a location for such facilities. GAO must consider (1) whether environmental or other regulations significantly delay and increase the cost of expanding or siting pharmaceutical manufacturing facilities in the United States; (2) the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency; and (3) specific actions for regulators to address the identified barriers.

Finally, the report must include recommendations for streamlining regulatory barriers and facilitating technological solutions to foster U.S. pharmaceutical manufacturing.



- Feb 18, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 18, 2025:** Introduced in House
  - **Feb 18, 2025:** Introduced in House
  - **Feb 18, 2025:** Referred to the House Committee on Energy and Commerce.
  - **Feb 18, 2025:** Introduced in House
  - **Feb 18, 2025:** Introduced in House
  - **Feb 18, 2025:** Referred to the House Committee on Energy and Commerce.
  - **Feb 18, 2025:** Introduced in House
  - **Feb 18, 2025:** Referred to the House Committee on Energy and Commerce.